Piper Jaffray analyst Christopher Raymond remains a buyer of Regeneron's shares after news of a 3% price increase for Dupixent, and "arguably less importantly" a 5% price increase for Kevzara. The analyst argues that while Dupixent's 3% increase is clearly more reasonable than the regular double-digit increases common in years past by other companies with other drugs, he does think it is notable given Regeneron's "strong and refreshingly honest" commentary around the industry's need for a different distribution and access model. Raymond believes this just further illustrates the fact that - despite the Trump Administration rhetoric regarding drug pricing - little has changed structurally. He reiterates an Overweight rating and $450 price target on the shares.